Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibogaine for Opioid Withdrawal
NCT05029401Phase 2Completed
- Sponsor
- atai Life Sciences
- Start
- Apr 2021
- Primary completion
- Jan 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ibogaine in opioid withdrawal syndrome (OWS), sponsored by atai Life Sciences. Started Apr 2021; status: completed.
02
Drugs
ibogaine
03
Conditions
opioid withdrawal syndrome (OWS)
Beyond the preview
Go deeper on NCT05029401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029401.